Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.
Sudarshan Pharma Industries's basic earnings per share (Basic EPS) for the
three
months ended in Mar. 2026 was ₹0.48.
Its basic earnings per share (Basic EPS) for the trailing twelve months (TTM) ended in Mar. 2026 was ₹0.98.
Sudarshan Pharma Industries's EPS without NRI for the
three
months ended in Mar. 2026 was ₹0.47.
Its EPS without NRIearnings per share without non-recurring items for the trailing twelve months (TTM) ended in Mar. 2026 was 0.97.
During the past 10 years, Sudarshan Pharma Industries's highest 3-Year average EPS without NRI Growth Rate was 100.20% per year. The lowest was 8.80% per year. And the median was 44.80% per year.
EPS is the single most important variable used by Wall Street in determining the earnings power of a company. But investors need to be aware that Earnings per Share can be easily manipulated by adjusting depreciation and amortization rate or non-recurring items. That's why GuruFocus lists EPS without NRI, which better reflects the company's underlying performance.
Be Aware
Compared with Earnings per share, a company's cash flow is better indicator of the company's earnings power.
If a company's earnings per share is less than cash flow per share over long term, investors need to be cautious and find out why.
Sudarshan Pharma Industries EPS (Basic) Related Terms
Sudarshan Pharma Industries EPS (Basic) Historical Data
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
EPS (Basic) is a rough measurement of the amount of a company's profit that can be allocated to one share of its stock. Basic earnings per share (EPS) do not factor in the dilutive effects on convertible securities.
EPS (Basic) for the trailing twelve months (TTM) ended in Mar. 2026 adds up the quarterly data reported by the company within the most recent 12 months, which was ₹0.98
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Sudarshan Pharma Industries (BOM:543828) has a EPS (Basic) of ₹0.98 as of Mar. 2026. Earnings per share (basic) equals net income divided by the standard, non-diluted average shares outstanding. View historical data on Sudarshan Pharma Industries and its competitors.
Is Sudarshan Pharma Industries' EPS (Basic) too high?
Sudarshan Pharma Industries' current EPS (Basic) is ₹0.98. Overall, Sudarshan Pharma Industries has a GF Score™ of 69/100 and is considered Significantly Overvalued, reflecting its overall financial health beyond just this single metric.
How does Sudarshan Pharma Industries' EPS (Basic) compare to DOW?
Sudarshan Pharma Industries' EPS (Basic) of ₹0.98 can be compared against companies in the Chemicals industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good EPS (Basic) for a Chemicals company?
A good EPS (Basic) depends on the Chemicals industry context. However, EPS (Basic) should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high EPS (Basic) mean?
A high EPS (Basic) can signal that a stock is expensive relative to its fundamentals. Earnings per share (basic) equals net income divided by the standard, non-diluted average shares outstanding. View historical data on Sudarshan Pharma Industries and its competitors. Sudarshan Pharma Industries's current EPS (Basic) is ₹0.98. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Sudarshan Pharma Industries stock overvalued right now?
Based on GuruFocus' analysis, Sudarshan Pharma Industries (BOM:543828) is currently considered Significantly Overvalued. The stock's GF Value™ is ₹6.52, compared to a current price of ₹32.49 — trading 398.3% above its estimated fair value. The current EPS (Basic) is ₹0.98. Sudarshan Pharma Industries' overall GF Score™ is 69/100 with 14 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is EPS (Basic) calculated?
EPS (Basic) is calculated from a company's financial statements. For Sudarshan Pharma Industries (BOM:543828), the current EPS (Basic) is ₹0.98 as of Mar. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Is Sudarshan Pharma Industries (BOM:543828) Overvalued in 2026?
Based on GuruFocus' analysis, Sudarshan Pharma Industries stock appears to be overvalued.
The current stock price of ₹32.49 is trading 398.3% above its estimated GF Value™ of ₹6.52.
GuruFocus considers Sudarshan Pharma Industries to be Significantly Overvalued.
Key valuation signals for BOM:543828:
EPS (Basic): ₹0.98
GF Value™: ₹6.52 vs. price of ₹32.49 (398.3% above fair value)
No single metric tells the full story. See the BOM:543828 stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.
Sudarshan Pharma Industries Ltd operates in the pharmaceutical and chemical industries, focusing on specialty chemicals and intermediates used in pharmaceuticals, paints, food products, and adhesives. The Company has a presence domestically and internationally, participating regularly in trade fairs and exhibitions. The Company exports mainly to South East Asia, the Middle East, and North Africa. The Company also supplies generic pharmaceutical formulation as 'Make to order' for bulk supply to hospitals and related healthcare organisations. The company has one reportable segment of Specialty Chemicals.
69GF Score
Get the complete analysis for BOM:543828
EPS (Basic) is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
BOM:543828 has been successfully added to your 
